Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FABP4 | P15090 | 4/20 | 0.58 |
| ▸ | FABP3 | P05413 | 2/20 | 0.58 |
| ▸ | FABP5 | Q01469 | 1/20 | 0.58 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | ACHE | P22303 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.45 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.41 |
| ▸ | F10 | P00742 | 2/20 | 0.39 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.38 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.38 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.36 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.36 |
| ▸ | PLAU | P00749 | 2/20 | 0.36 |
| ▸ | PLG | P00747 | 1/20 | 0.36 |
| ▸ | PLAT | P00750 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Acetone SCHEMBL5392765 | 0.93 | FABP4 (0.56) | FABP4FABP3FABP5GAAACHE | |
| SCHEMBL21297046 | 0.93 | FABP4 (0.51) | FABP4FABP3FABP5GAAACHE | |
| SCHEMBL27434290 | 0.85 | FABP4 (0.55) | FABP4FABP3FABP5GAAACHE | |
| SCHEMBL21922801 | 0.84 | FABP4 (0.62) | FABP4FABP3FABP5GAATDP1 | |
| Benzaldehyde SCHEMBL16934845 | 0.84 | HDAC1 (0.44) | FABP4FABP3FABP5GAAACHE | |
| SCHEMBL10452159 | 0.82 | FABP4 (0.60) | FABP4FABP3FABP5GAATDP1 | |
| SCHEMBL1767682 | 0.81 | FABP4 (0.63) | FABP4FABP3FABP5GAATDP1 | |
| SCHEMBL14616652 | 0.79 | FABP4 (0.56) | FABP4FABP3FABP5GAATDP1 | |
| SCHEMBL1069046 | 0.78 | FABP4 (0.64) | FABP4FABP3FABP5GAATDP1 | |
| SCHEMBL17115758 | 0.78 | FABP4 (0.50) | FABP4FABP3FABP5GAATDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 411 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118460757-A | Method for screening dendrobium candidum hybrid parents by using EST-SSR primers | 浙江寿仙谷医药股份有限公司 | 2024-08-09 | — | — | CN | claimed |
| CN-117705988-A | Method for measuring anhydride value in anhydride-containing copolymer after derivatization | 江苏扬农化工集团有限公司 | 2024-03-15 | — | — | CN | claimed |
| CN-112707779-B | Preparation method of vinylcyclohexane | 蚌埠中实化学技术有限公司 | 2023-06-30 | — | — | CN | claimed |
| EP-3670490-B1 | METHOD OF PURIFYING PINE CHEMICAL COMPOSITIONS FROM ALDEHYDES | KRATON POLYMERS LLC (US) | 2023-01-18 | — | — | EP | claimed |
| CN-110746633-B | Preparation method of microporous polymethacrylimide foam | 浙江中科恒泰新材料科技有限公司 | 2022-08-16 | — | — | CN | claimed |
| CN-112707779-A | Preparation method of vinyl cyclohexane | 蚌埠中实化学技术有限公司 | 2021-04-27 | — | — | CN | claimed |
| CN-108059599-B | Preparation method of Venetong key intermediate | 凯方医药科技（上海）有限公司 | 2020-08-21 | — | — | CN | claimed |
| EP-3670490-A1 | METHOD OF PURIFYING PINE CHEMICAL COMPOSITIONS FROM ALDEHYDES | Kraton Polymers LLC (US) | 2020-06-24 | — | — | EP | claimed |
| US-20200165191-A1 | Method of Purifying Pine Chemical Compositions from Aldehydes | KRATON POLYMERS LLC (US) | 2020-05-28 | — | — | US | claimed |
| CN-110746633-A | Preparation method of microporous polymethacrylimide foam | 浙江中科恒泰新材料科技有限公司 | 2020-02-04 | — | — | CN | claimed |
| CN-103664852-B | Preparation method of rose ether | UNIV LANGZHOU | 2015-05-13 | — | — | CN | claimed |
| CN-104130229-A | Preparation method of cis-rose oxide | UNIV LANZHOU | 2014-11-05 | — | — | CN | claimed |
| CN-103664852-A | Preparation method of rose ether | UNIV LANGZHOU | 2014-03-26 | — | — | CN | claimed |
| US-8399671-B2 | Methods for producing hydrocodone, hydromorphone or a derivative thereof | MALLINCKRODT LLC (US) | 2013-03-19 | — | — | US | claimed |
| EP-2480555-A2 | METHODS FOR PRODUCING HYDROCODONE, HYDROMORPHONE OR A DERIVATIVE THEREOF | Mallinckrodt LLC (US) | 2012-08-01 | — | — | EP | claimed |
| WO-2011037854-A2 | METHODS FOR PRODUCING HYDROCODONE, HYDROMORPHONE OR A DERIVATIVE THEREOF | MALLINCKRODT INC. (US) | 2011-03-31 | — | — | WO | claimed |
| US-20110071297-A1 | Methods for Producing Hydrocodone, Hydromorphone or a Derivative Thereof | MALLINCKRODT INC. (US) | 2011-03-24 | — | — | US | claimed |
| CN-100364995-C | Production of galantamine | UNIV LANZHOU (CN) | 2008-01-30 | — | — | CN | claimed |
| US-20060009479-A1 | Process for the synthesis of hydromorphone | BAILEY TIMOTHY S | 2006-01-12 | — | — | US | claimed |
| US-12239639-B2 | Cytotoxic actin-targeting compounds | QUEEN'S UNIVERSITY AT KINGSTON (CA) | 2025-03-04 | — | — | US | disclosed |
| CN-222291100-U | Dendrobium nobile juice production juicer | 霍山县众康堂中药材开发有限公司 | 2025-01-03 | — | — | CN | disclosed |
| US-20240327342-A1 | COMPOUNDS HAVING S1P5 RECEPTOR AGONISTIC ACTIVITY | ONO PHARMACEUTICAL CO., LTD. (JP) | 2024-10-03 | — | — | US | disclosed |
| EP-4431157-A2 | 1-[[(3S)-3-METHYL-6-(4(4,4-TRIFLUOROBUTOXY)-3,4-DIHYDRONAPHTHALEN-2YL]METHYL]AZETIDINE-3-CARBOXYLIC ACID HAVING S1P5 RECEPTOR AGONIST ACTIVITY FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS AND CANCER | ONO Pharmaceutical Co., Ltd. (JP) | 2024-09-18 | — | — | EP | disclosed |
| US-12084448-B2 | Process for the cycloaddition of a (hetero)aryl 1,3-dipole compound with a (hetero)cycloalkyne | SYNAFFIX B.V. (NL) | 2024-09-10 | — | — | US | disclosed |
| CN-118460757-A | Method for screening dendrobium candidum hybrid parents by using EST-SSR primers | 浙江寿仙谷医药股份有限公司 | 2024-08-09 | — | — | CN | disclosed |
| US-12049445-B2 | Compounds having S1P5 receptor agonistic activity | ONO PHARMACEUTICAL CO., LTD. (JP) | 2024-07-30 | — | — | US | disclosed |
| CN-118108674-A | Substituted pyridazinones as herbicides | 先正达农作物保护股份公司 | 2024-05-31 | — | — | CN | disclosed |
| CN-118084802-A | Substituted pyridazinones as herbicides | 先正达农作物保护股份公司 | 2024-05-28 | — | — | CN | disclosed |
| CN-115111701-B | Air conditioner control method, controller, air conditioner and storage medium | 广东美的制冷设备有限公司 | 2024-05-28 | — | — | CN | disclosed |
| CN-118084803-A | Substituted pyridazinones as herbicides | 先正达农作物保护股份公司 | 2024-05-28 | — | — | CN | disclosed |
| US-20240166619-A1 | CROWN ETHER CARBENES AND METHODS OF USE | PALL CORP (US) | 2024-05-23 | — | — | US | disclosed |
| EP-4371986-A2 | SUBSTITUTED PYRIDAZINONES AS HERBICIDES | Syngenta Crop Protection AG (CH) | 2024-05-22 | — | — | EP | disclosed |
| WO-2024097030-A1 | CROWN ETHER CARBENES AND METHODS OF USE | PALL CORPORATION (US) | 2024-05-10 | — | — | WO | disclosed |
| US-11976083-B2 | Inhibitors of peptidylarginine deiminases | GILEAD SCIENCES, INC. (US) | 2024-05-07 | — | — | US | disclosed |
| EP-4357344-A2 | SUBSTITUTED PYRIDAZINONES AS HERBICIDES | Syngenta Crop Protection AG (CH) | 2024-04-24 | — | — | EP | disclosed |
| CN-115551862-B | Macrocyclic inhibitors of peptidyl arginine deiminase | 吉利德科学公司 | 2024-04-12 | — | — | CN | disclosed |
| EP-3999503-B1 | SUBSTITUTED PYRIDAZINONES AS HERBICIDES | SYNGENTA CROP PROTECTION AG (CH) | 2024-04-03 | — | — | EP | disclosed |
| WO-2024064731-A2 | RAPID ENTRY INTO COTYLENIN CHEMICAL SPACE FOR DEVELOPMENT OF SELECTIVE 14-3-3 MOLECULAR GLUES | THE SCRIPPS RESEARCH INSTITUTE (US) | 2024-03-28 | — | — | WO | disclosed |
| CN-117705988-A | Method for measuring anhydride value in anhydride-containing copolymer after derivatization | 江苏扬农化工集团有限公司 | 2024-03-15 | — | — | CN | disclosed |
| US-11905269-B1 | Crown ether carbenes and methods of use | PALL CORPORATION (US) | 2024-02-20 | — | — | US | disclosed |
| CN-220447271-U | Dendrobium candidum juice production juicer | 浙江铁枫堂药业有限公司 | 2024-02-06 | — | — | CN | disclosed |
| US-11834482-B2 | Agents modulating beta-catenin functions and methods thereof | FOG PHARMACEUTICALS, INC. (US) | 2023-12-05 | — | — | US | disclosed |
| EP-3908451-B1 | THREE-DIMENSIONAL PRINTING | HEWLETT PACKARD DEVELOPMENT CO (US) | 2023-11-29 | — | — | EP | disclosed |
| CN-117053283-A | Air conditioner control method, controller, air conditioner and storage medium | 广东美的制冷设备有限公司 | 2023-11-14 | — | — | CN | disclosed |
| EP-3464297-B1 | PROCESS FOR PREPARATION OF ERIBULIN AND INTERMEDIATES THEREOF | Dr Reddys Laboratories Ltd (IN) | 2023-10-25 | — | — | EP | disclosed |
| CN-114917298-B | Pharmaceutical composition for treating pneumonia and preparation method thereof | 森隆药业有限公司 | 2023-10-20 | — | — | CN | disclosed |
| EP-4238979-A1 | BETA-STRAND TYPE CROSSLINKED PEPTIDE | Xeno-Interface Inc. (JP) | 2023-09-06 | — | — | EP | disclosed |
| EP-4237131-A1 | LOW METAL CONTENT POLYOLEFIN FILTER MEMBRANE | Entegris, Inc. (US) | 2023-09-06 | — | — | EP | disclosed |
| CN-116710116-A | Beta-sheet femoral bridge peptide | Ｘｅｎｏ－Ｉｎｔｅｒｆａｃｅ株式会社 | 2023-09-05 | — | — | CN | disclosed |
| CN-116425740-A | Quinine hydrazone derivative and preparation method and application thereof | 河南科技大学 | 2023-07-14 | — | — | CN | disclosed |
| CN-112707779-B | Preparation method of vinylcyclohexane | 蚌埠中实化学技术有限公司 | 2023-06-30 | — | — | CN | disclosed |
| CN-112707779-B | Preparation method of vinylcyclohexane | 蚌埠中实化学技术有限公司 | 2023-06-30 | — | — | CN | disclosed |
| CN-219213298-U | Regulation structure and slicer is used in dendrobium officinale processing | 安徽牧龙山铁皮石斛生物科技开发有限公司 | 2023-06-20 | — | — | CN | disclosed |
| WO-2023107787-A1 | FUNCTIONAL CYCLIC OLEFIN POLYMER, PROCESS FOR OBTAINING THE SAME AND COMPOSITIONS CONTAINING THE SAME | EXXONMOBIL CHEMICAL PATENTS INC. (US) | 2023-06-15 | — | — | WO | disclosed |
| US-20230174576-A1 | BETA-STRAND BRIDGE PEPTIDE | KYOTO UNIVERSITY (JP) | 2023-06-08 | — | — | US | disclosed |
| CN-115935650-A | Energy storage and pumped storage multi-state conversion clearing model construction method and device in electric power spot market environment | 国网四川省电力公司 | 2023-04-07 | — | — | CN | disclosed |
| CN-115770651-A | Preparation for treating hyperglycemia by fermenting Chinese herbal medicines in the aged and preparation device | 江苏春江生物科技有限公司 | 2023-03-10 | — | — | CN | disclosed |
| EP-4143189-A1 | MACROCYCLIC INHIBITORS OF PEPTIDYLARGININE DEIMINASES | GILEAD SCIENCES, INC. (US) | 2023-03-08 | — | — | EP | disclosed |
| US-20230037322-A1 | Cytotoxic Actin-Targeting Compounds | QUEEN'S UNIVERSITY AT KINGSTON (CA) | 2023-02-09 | — | — | US | disclosed |
| CN-115671221-A | Traditional Chinese medicine composition for restoring vitality and consolidating foundation and preparation method thereof | 陈娟 | 2023-02-03 | — | — | CN | disclosed |
| CN-115636712-A | Preparation method of alkyl alkenyl cyclohexane | 山东京博石油化工有限公司 | 2023-01-24 | — | — | CN | disclosed |
| EP-3670490-B1 | METHOD OF PURIFYING PINE CHEMICAL COMPOSITIONS FROM ALDEHYDES | KRATON POLYMERS LLC (US) | 2023-01-18 | — | — | EP | disclosed |
| CN-115574431-A | Control method of air conditioner, controller, air conditioner and readable storage medium | 广东美的制冷设备有限公司 | 2023-01-06 | — | — | CN | disclosed |
| US-20230002412-A1 | INHIBITORS OF PEPTIDYLARGININE DEIMINASES | GILEAD SCIENCES, INC. | 2023-01-05 | — | — | US | disclosed |
| CN-115551862-A | Macrocyclic inhibitors of peptidyl arginine deiminase | 吉利德科学公司 | 2022-12-30 | — | — | CN | disclosed |
| CN-110698328-B | Method for using dihydroresveratrol or stilbene derivatives and/or chemical variants thereof as antimicrobial agents | 香港浸会大学 | 2022-12-20 | — | — | CN | disclosed |
| CN-115125084-A | Vintage-brewed health-preserving wine and brewing method thereof | 胡忠龙 | 2022-09-30 | — | — | CN | disclosed |
| CN-115111701-A | Control method of air conditioner, controller, air conditioner and storage medium | 广东美的制冷设备有限公司 | 2022-09-27 | — | — | CN | disclosed |
| US-20220281837-A1 | SUBSTITUTED PYRIDAZINONES AS HERBICIDES | SYNGENTA CROP PROTECTION AG (CH) | 2022-09-08 | — | — | US | disclosed |
| CN-114917298-A | Pharmaceutical composition for treating pneumonia and preparation method thereof | 森隆药业有限公司 | 2022-08-19 | — | — | CN | disclosed |
| CN-110746633-B | Preparation method of microporous polymethacrylimide foam | 浙江中科恒泰新材料科技有限公司 | 2022-08-16 | — | — | CN | disclosed |
| US-20220213154-A1 | AGENTS MODULATING BETA-CATENIN FUNCTIONS AND METHODS THEREOF | PARABILIS MEDICINES, INC. | 2022-07-07 | — | — | US | disclosed |
| US-11369594-B2 | Cytotoxic actin-targeting compounds | QUEEN'S UNIVERSITY AT KINGSTON (CA) | 2022-06-28 | — | — | US | disclosed |
| CN-114555563-A | Substituted pyridazinones as herbicides | 先正达农作物保护股份公司 | 2022-05-27 | — | — | CN | disclosed |
| EP-3999494-A2 | SUBSTITUTED PYRIDAZINONES AS HERBICIDES | Syngenta Crop Protection AG (CH) | 2022-05-25 | — | — | EP | disclosed |
| EP-3999503-A1 | SUBSTITUTED PYRIDAZINONES AS HERBICIDES | Syngenta Crop Protection AG (CH) | 2022-05-25 | — | — | EP | disclosed |
| CN-113621015-B | 7-dehydrocholesterol and preparation method thereof | 浙江新和成药业有限公司 | 2022-05-17 | — | — | CN | disclosed |
| CN-114432911-A | Low metal content polyolefin filtration membranes | 恩特格里斯公司 | 2022-05-06 | — | — | CN | disclosed |
| WO-2022094026-A1 | LOW METAL CONTENT POLYOLEFIN FILTER MEMBRANE | ENTEGRIS, INC. (US) | 2022-05-05 | — | — | WO | disclosed |
| WO-2022092295-A1 | β-STRAND TYPE CROSSLINKED PEPTIDE | Ｘｅｎｏ－Ｉｎｔｅｒｆａｃｅ株式会社 | 2022-05-05 | — | — | WO | disclosed |
| US-20220134293-A1 | LOW METAL CONTENT POLYOLEFIN FILTER MEMBRANE | MORGAN STANLEY SENIOR FUNDING, INC., AS COLLATERAL AGENT | 2022-05-05 | — | — | US | disclosed |
| CN-109952286-B | Skin protection composition based on dendrobe components | 香港浸会大学 | 2022-03-22 | — | — | CN | disclosed |
| US-11271842-B2 | Enhancing transmission control protocol (TCP) performance and scalability on multicore processor architectures | SPIRENT COMMUNICATIONS, INC. (US) | 2022-03-08 | — | — | US | disclosed |
| CN-114144409-A | Substituted pyridazinones as herbicides | 先正达农作物保护股份公司 | 2022-03-04 | — | — | CN | disclosed |
| US-20220056284-A1 | THREE-DIMENSIONAL PRINTING | HEWLETT-PACKARD DEVELOPMENT COMPANY, L.P. (US) | 2022-02-24 | — | — | US | disclosed |
| US-20220055986-A1 | COMPOUNDS HAVING S1P5 RECEPTOR AGONISTIC ACTIVITY | ONO PHARMACEUTICAL CO., LTD. (JP) | 2022-02-24 | — | — | US | disclosed |
| US-20220048920-A1 | PROCESS FOR THE CYCLOADDITION OF A (HETERO)ARYL 1,3-DIPOLE COMPOUND WITH A (HETERO)CYCLOALKYNE | SYNAFFIX B.V. (NL) | 2022-02-17 | — | — | US | disclosed |
| US-20220049120-A1 | THREE-DIMENSIONAL PRINTING | HEWLETT-PACKARD DEVELOPMENT COMPANY, L.P. (US) | 2022-02-17 | — | — | US | disclosed |
| US-11236128-B2 | Method of preparing stapled peptides | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2022-02-01 | — | — | US | disclosed |
| EP-3925951-A1 | PROCESS FOR THE CYCLOADDITION OF A(HETERO)ARYL 1,3-DIPOLE COMPOUND WITH A (HETERO)CYCLOALKYNE | SynAffix B.V. (NL) | 2021-12-22 | — | — | EP | disclosed |
| US-11203708-B2 | Gas generating compositions | SAUDI ARABIAN OIL COMPANY (SA) | 2021-12-21 | — | — | US | disclosed |
| US-11198672-B2 | Compounds having S1P5 receptor agonistic activity | ONO PHARMACEUTICAL CO., LTD. (JP) | 2021-12-14 | — | — | US | disclosed |
| US-11198713-B2 | Agents modulating beta-catenin functions and methods thereof | FOG PHARMACEUTICALS, INC. (US) | 2021-12-14 | — | — | US | disclosed |
| EP-3908451-A1 | THREE-DIMENSIONAL PRINTING | Hewlett-Packard Development Company, L.P. (US) | 2021-11-17 | — | — | EP | disclosed |
| US-11168085-B2 | Process for the cycloaddition of a hetero(aryl) 1,3-dipole compound with a (hetero)cycloalkyne | SYNAFFIX B.V. (NL) | 2021-11-09 | — | — | US | disclosed |
| CN-113621015-A | 7-dehydrocholesterol and preparation method thereof | 浙江新和成药业有限公司 | 2021-11-09 | — | — | CN | disclosed |
| WO-2021222353-A1 | MACROCYCLIC INHIBITORS OF PEPTIDYLARGININE DEIMINASES | GILEAD SCIENCES, INC. (US) | 2021-11-04 | — | — | WO | disclosed |
| US-20210300878-A1 | CONTRAST AGENTS FOR MYOCARDIAL PERFUSION IMAGING | LANTHEUS MEDICAL IMAGING, INC. (US) | 2021-09-30 | — | — | US | disclosed |
| US-11059799-B2 | Process for preparation of eribulin and intermediates thereof | DR. REDDY'S LABORATORIES LIMITED. (IN) | 2021-07-13 | — | — | US | disclosed |
| US-20210139538-A1 | METHOD OF PREPARING STAPLED PEPTIDES | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2021-05-13 | — | — | US | disclosed |
| EP-3097079-B1 | PROCESS FOR THE CYCLOADDITION OF A HETERO(ARYL) 1,3-DIPOLE COMPOUND WITH A (HETERO)CYCLOALKYNE | SYNAFFIX BV (NL) | 2021-05-12 | — | — | EP | disclosed |
| CN-112707779-A | Preparation method of vinyl cyclohexane | 蚌埠中实化学技术有限公司 | 2021-04-27 | — | — | CN | disclosed |
| CN-112707779-A | Preparation method of vinyl cyclohexane | 蚌埠中实化学技术有限公司 | 2021-04-27 | — | — | CN | disclosed |
| EP-3385253-B1 | CONTRAST AGENTS FOR MYOCARDIAL PERFUSION IMAGING | LANTHEUS MEDICAL IMAGING INC (US) | 2021-04-07 | — | — | EP | disclosed |
| US-20210087141-A1 | COMPOUNDS HAVING S1P5 RECEPTOR AGONISTIC ACTIVITY | ONO PHARMACEUTICAL CO., LTD. (JP) | 2021-03-25 | — | — | US | disclosed |
| US-10934468-B2 | Storable gas generating compositions | SAUDI ARABIAN OIL COMPANY (SA) | 2021-03-02 | — | — | US | disclosed |
| US-20210047552-A1 | GAS GENERATING COMPOSITIONS | ARAMCO SERVICES COMPANY | 2021-02-18 | — | — | US | disclosed |
| WO-2021009334-A2 | HERBICIDAL COMPOUNDS | SYNGENTA CROP PROTECTION AG (CH) | 2021-01-21 | — | — | WO | disclosed |
| WO-2021009335-A1 | SUBSTITUTED PYRIDAZINONES AS HERBICIDES | SYNGENTA CROP PROTECTION AG (CH) | 2021-01-21 | — | — | WO | disclosed |
| EP-3555102-B1 | HERBICIDAL COMPOUNDS | SYNGENTA PARTICIPATIONS AG (CH) | 2021-01-20 | — | — | EP | disclosed |
| US-10889550-B2 | Contrast agents for myocardial perfusion imaging | LANTHEUS MEDICAL IMAGING, INC. (US) | 2021-01-12 | — | — | US | disclosed |
| EP-3757091-A1 | COMPOUND HAVING S1P5 RECEPTOR AGONIST ACTIVITY | ONO Pharmaceutical Co., Ltd. (JP) | 2020-12-30 | — | — | EP | disclosed |
| US-10858565-B2 | Gas generating compositions | SAUDI ARABIAN OIL COMPANY (SA) | 2020-12-08 | — | — | US | disclosed |
| US-10822302-B2 | Method of purifying pine chemical compositions from aldehydes | KRATON POLYMERS LLC (US) | 2020-11-03 | — | — | US | disclosed |
| CN-111757869-A | Compounds having S1P5 receptor agonistic activity | 小野药品工业株式会社 | 2020-10-09 | — | — | CN | disclosed |
| US-20200306233-A1 | Cytotoxic Actin-Targeting Compounds | QUEEN'S UNIVERSITY AT KINGSTON (CA) | 2020-10-01 | — | — | US | disclosed |
| US-20200270505-A1 | STORABLE GAS GENERATING COMPOSITIONS | SAUDI ARABIAN OIL COMPANY (SA) | 2020-08-27 | — | — | US | disclosed |
| US-20200270502-A1 | GAS GENERATING COMPOSITIONS | SAUDI ARABIAN OIL COMPANY (SA) | 2020-08-27 | — | — | US | disclosed |
| CN-108059599-B | Preparation method of Venetong key intermediate | 凯方医药科技（上海）有限公司 | 2020-08-21 | — | — | CN | disclosed |
| US-20200247858-A1 | AGENTS MODULATING BETA-CATENIN FUNCTIONS AND METHODS THEREOF | FOG PHARMACEUTICALS, INC. (US) | 2020-08-06 | — | — | US | disclosed |
| CN-110540535-B | Process suitable for preparing 4- (6-aminopyridin-3-yl) substituted piperidine in amplification way | 上海再启生物技术有限公司 | 2020-07-31 | — | — | CN | disclosed |
| EP-3678683-A2 | AGENTS MODULATING BETA-CATENIN FUNCTIONS AND METHODS THEREOF | Fog Pharmaceuticals, Inc. (US) | 2020-07-15 | — | — | EP | disclosed |
| CN-111372942-A | β -catenin function modulating agents and methods thereof | 弗格制药有限公司 | 2020-07-03 | — | — | CN | disclosed |
| EP-3670490-A1 | METHOD OF PURIFYING PINE CHEMICAL COMPOSITIONS FROM ALDEHYDES | Kraton Polymers LLC (US) | 2020-06-24 | — | — | EP | disclosed |
| US-20200165191-A1 | Method of Purifying Pine Chemical Compositions from Aldehydes | KRATON POLYMERS LLC (US) | 2020-05-28 | — | — | US | disclosed |
| US-20200113181-A1 | HERBICIDAL COMPOUNDS | SYNGENTA PARTICIPATIONS AG (CH) | 2020-04-16 | — | — | US | disclosed |
| WO-2020070050-A1 | FUNGICIDAL 5-SUBSTITUTED IMIDAZOL-1-YL CARBINOL DERIVATIVES | BAYER AKTIENGESELLSCHAFT (DE) | 2020-04-09 | — | — | WO | disclosed |
| US-10590326-B1 | Storable gas generating compositions | SAUDI ARABIAN OIL COMPANY (SA) | 2020-03-17 | — | — | US | disclosed |
| CN-110746633-A | Preparation method of microporous polymethacrylimide foam | 浙江中科恒泰新材料科技有限公司 | 2020-02-04 | — | — | CN | disclosed |
| CN-110540535-A | process suitable for preparing 4- (6-aminopyridin-3-yl) substituted piperidine in amplification way | SHANGHAI ZAIQI BIO TECH CO LTD | 2019-12-06 | — | — | CN | disclosed |
| EP-3555102-A1 | HERBICIDAL COMPOUNDS | Syngenta Participations AG (CH) | 2019-10-23 | — | — | EP | disclosed |
| CN-110088109-A | HERBICIDAL COMPOUNDS | 先正达参股股份有限公司 | 2019-08-02 | — | — | CN | disclosed |
| US-20190177291-A1 | PROCESS FOR PREPARATION OF ERIBULIN AND INTERMEDIATES THEREOF | DR. REDDY'S LABORATORIES LIMITED (IN) | 2019-06-13 | — | — | US | disclosed |
| EP-2970122-B1 | SHIP1 MODULATORS | AQUINOX PHARMACEUTICALS CANADA INC (CA) | 2019-05-08 | — | — | EP | disclosed |
| US-20190125870-A1 | PHOTOCLEAVABLE DRUG CONJUGATES | THE CURATORS OF THE UNIVERSITY OF MISSOURI | 2019-05-02 | — | — | US | disclosed |
| US-20190127333-A1 | CONTRAST AGENTS FOR MYOCARDIAL PERFUSION IMAGING | LANTHEUS MEDICAL IMAGING, INC. (US) | 2019-05-02 | — | — | US | disclosed |
| US-10272081-B2 | SHIP1 modulators and methods related thereto | AQUINOX PHARMACEUTICALS (CANADA) INC. (CA) | 2019-04-30 | — | — | US | disclosed |
| WO-2019051327-A2 | AGENTS MODULATING BETA-CATENIN FUNCTIONS AND METHODS THEREOF | FOG PHARMACEUTICALS, INC. (US) | 2019-03-14 | — | — | WO | disclosed |
| CN-109415383-A | Method for preparing eribulin and intermediate thereof | 雷迪博士实验室有限公司 | 2019-03-01 | — | — | CN | disclosed |
| WO-2019033219-A1 | CYTOTOXIC ACTIN-TARGETING COMPOUNDS | QUEEN'S UNIVERSITY AT KINGSTON (CA) | 2019-02-21 | — | — | WO | disclosed |
| US-10202399-B2 | Dihydroxy aromatic heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2019-02-12 | — | — | US | disclosed |
| WO-2019027368-A1 | METHOD OF PREPARING STAPLED PEPTIDES | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2019-02-07 | — | — | WO | disclosed |
| US-20190023709-A1 | SHIP1 MODULATORS AND METHODS RELATED THERETO | AQUINOX PHARMACEUTICALS CANADA INC (CA) | 2019-01-24 | — | — | US | disclosed |
| US-10174046-B2 | SHIP1 modulators and methods related thereto | AQUINOX PHARMACEUTICALS (CANADA) INC. (CA) | 2019-01-08 | — | — | US | disclosed |
| US-10159735-B2 | Photocleavable drug conjugates | THE CURATORS OF THE UNIVERSITY OF MISSOURI (US) | 2018-12-25 | — | — | US | disclosed |
| US-20180360828-A9 | SHIP1 MODULATORS AND METHODS RELATED THERETO | NEOLEUKIN THERAPEUTICS, INC. | 2018-12-20 | — | — | US | disclosed |
| US-10155771-B2 | Selective reduction of morphinan alkaloids | NORAMCO, INC. (US) | 2018-12-18 | — | — | US | disclosed |
| CN-108997142-A | Remove the method that ketone is remained in ketone method production fatty amine | 浙江建业化工股份有限公司 | 2018-12-14 | — | — | CN | disclosed |
| US-10125106-B2 | Contrast agents for myocardial perfusion imaging | LANTHEUS MEDICAL IMAGING, INC. (US) | 2018-11-13 | — | — | US | disclosed |
| US-10100056-B2 | SHIP1 modulators and methods related thereto | AQUINOX PHARMACEUTICALS (CANADA) INC. (CA) | 2018-10-16 | — | — | US | disclosed |
| EP-3385253-A1 | CONTRAST AGENTS FOR MYOCARDIAL PERFUSION IMAGING | Lantheus Medical Imaging, Inc. (US) | 2018-10-10 | — | — | EP | disclosed |
| WO-2018114584-A1 | HERBICIDAL COMPOUNDS | SYNGENTA PARTICIPATIONS AG (CH) | 2018-06-28 | — | — | WO | disclosed |
| US-20180161324-A1 | SHIP1 MODULATORS AND METHODS RELATED THERETO | AQUINOX PHARMACEUTICALS CANADA INC (CA) | 2018-06-14 | — | — | US | disclosed |
| US-20180155359-A9 | SHIP1 MODULATORS AND METHODS RELATED THERETO | TARO PHARMACEUTICALS INC. (CA) | 2018-06-07 | — | — | US | disclosed |
| CN-108059599-A | A kind of preparation method of Wei Naituoke key intermediates | 凯方医药科技（上海）有限公司 | 2018-05-22 | — | — | CN | disclosed |
| US-9937167-B2 | SHIP1 modulators and methods related thereto | AQUINOX PHARMACEUTICALS (CANADA) INC. (CA) | 2018-04-10 | — | — | US | disclosed |
| US-20180009763-A1 | CONTRAST AGENTS FOR MYOCARDIAL PERFUSION IMAGING | LANTHEUS MEDICAL IMAGING, INC. (US) | 2018-01-11 | — | — | US | disclosed |
| EP-1713512-B1 | CONTRAST AGENTS FOR MYOCARDIAL PERFUSION IMAGING | LANTHEUS MEDICAL IMAGING INC (US) | 2018-01-10 | — | — | EP | disclosed |
| EP-2834239-B1 | HETEROBICYCLIC COMPOUNDS AS BETA-LACTAMASE INHIBITORS | ENTASIS THERAPEUTICS LTD (GB) | 2017-12-27 | — | — | EP | disclosed |
| US-20170362250-A1 | SHIP1 MODULATORS AND METHODS RELATED THERETO | AQUINOX PHARMACEUTICALS (CANADA) INC (CA) | 2017-12-21 | — | — | US | disclosed |
| US-9765085-B2 | SHIP1 modulators and methods related thereto | AQUINOX PHARMACEUTICALS (CANADA) INC. (CA) | 2017-09-19 | — | — | US | disclosed |
| US-20170253596-A2 | SHIP1 MODULATORS AND METHODS RELATED THERETO | TARO PHARMACEUTICALS INC. (CA) | 2017-09-07 | — | — | US | disclosed |
| US-20170247389-A2 | SHIP1 MODULATORS AND METHODS RELATED THERETO | TARO PHARMACEUTICALS INC. (CA) | 2017-08-31 | — | — | US | disclosed |
| US-20170224682-A1 | SHIP1 MODULATORS AND METHODS RELATED THERETO | NEOLEUKIN THERAPEUTICS, INC. | 2017-08-10 | — | — | US | disclosed |
| US-9718786-B2 | Contrast agents for myocardial perfusion imaging | LANTHEUS MEDICAL IMAGING, INC. (US) | 2017-08-01 | — | — | US | disclosed |
| US-20170137432-A1 | SELECTIVE REDUCTION OF MORPHINAN ALKALOIDS | NORAMCO INC. (US) | 2017-05-18 | — | — | US | disclosed |
| EP-3162438-A1 | POLYMER SUPPORTED VICINAL DIAMINES AND THEIR USE AS CATALYST IN THE HAJOS-PARRISH-ENDER-SAUSER-WIECHERT AND ROBINSON ANNULATION REACTIONS | Fundació Institut Català d'Investigació Química (ES) | 2017-05-03 | — | — | EP | disclosed |
| US-20170107226-A1 | DIHYDROXY AROMATIC HETEROCYCLIC COMPOUND | ASTELLAS PHARMA INC. (JP) | 2017-04-20 | — | — | US | disclosed |
| US-9623014-B2 | β-lactamase inhibitor compounds | ENTASIS THERAPEUTICS LIMITED (GB) | 2017-04-18 | — | — | US | disclosed |
| CN-104364254-B | Heterobicyclic compounds as beta-lactamase inhibitors | 恩塔西斯治疗有限公司 | 2017-02-22 | — | — | CN | disclosed |
| US-9562020-B2 | Dihydroxy aromatic heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-02-07 | — | — | US | disclosed |
| US-9540353-B2 | SHIP1 modulators and methods related thereto | AQUINOX PHARMACEUTICALS (CANADA) INC. (CA) | 2017-01-10 | — | — | US | disclosed |
| US-20170002012-A1 | PROCESS FOR THE CYCLOADDITION OF A HETERO(ARYL) 1,3-DIPOLE COMPOUND WITH A (HETERO)CYCLOALKYNE | SYNAFFIX B.V. (NL) | 2017-01-05 | — | — | US | disclosed |
| EP-3097079-A1 | PROCESS FOR THE CYCLOADDITION OF A HETERO(ARYL) 1,3-DIPOLE COMPOUND WITH A (HETERO)CYCLOALKYNE | SynAffix B.V. (NL) | 2016-11-30 | — | — | EP | disclosed |
| US-20160257671-A2 | SHIP1 MODULATORS AND METHODS RELATED THERETO | NEOLEUKIN THERAPEUTICS, INC. | 2016-09-08 | — | — | US | disclosed |
| CN-105001038-B | A kind of synthesis is together with the method for dihalide compound | 沧州普瑞东方科技有限公司 | 2016-07-06 | — | — | CN | disclosed |
| US-20160175290-A1 | BETA-LACTAMASE INHIBITOR COMPOUNDS | ASTRAZENECA PHARMACEUTICALS LP | 2016-06-23 | — | — | US | disclosed |
| US-9347961-B2 | Test kit for the quantitative determination of narcotic drugs | CHIRON AS (NO) | 2016-05-24 | — | — | US | disclosed |
| US-20160130235-A1 | CONTRAST AGENTS FOR MYOCARDIAL PERFUSION IMAGING | LANTHEUS MEDICAL IMAGING, INC. (US) | 2016-05-12 | — | — | US | disclosed |
| US-20160102058-A1 | FLUORO-PERHEXILINE COMPOUNDS AND THEIR THERAPEUTIC USE | THE UNIVERSITY COURT OF THE UNIVERSITY OF ABERDEEN (GB) | 2016-04-14 | — | — | US | disclosed |
| US-20160102058-A1 | FLUORO-PERHEXILINE COMPOUNDS AND THEIR THERAPEUTIC USE | THE UNIVERSITY COURT OF THE UNIVERSITY OF ABERDEEN (GB) | 2016-04-14 | — | — | US | disclosed |
| US-20160102058-A1 | FLUORO-PERHEXILINE COMPOUNDS AND THEIR THERAPEUTIC USE | THE UNIVERSITY COURT OF THE UNIVERSITY OF ABERDEEN (GB) | 2016-04-14 | — | — | US | disclosed |
| US-9309245-B2 | Beta-lactamase inhibitor compounds | ENTASIS THERAPEUTICS LIMITED (GB) | 2016-04-12 | — | — | US | disclosed |
| US-20160083387-A1 | SHIP1 MODULATORS AND METHODS RELATED THERETO | AQUINOX PHARMACEUTICALS CANADA INC (CA) | 2016-03-24 | — | — | US | disclosed |
| EP-2997012-A1 | FLUORO-PERHEXILINE COMPOUNDS AND THEIR THERAPEUTIC USE | The University Court of The University of Aberdeen (GB) | 2016-03-23 | — | — | EP | disclosed |
| CN-104130229-B | A kind of preparation method of cis-rose oxide | LANZHOU UNIVERSITY (CN) | 2016-03-09 | — | — | CN | disclosed |
| US-20160039771-A1 | DIHYDROXY AROMATIC HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL (JP) | 2016-02-11 | — | — | US | disclosed |
| US-20160031899-A1 | SHIP1 MODULATORS AND METHODS RELATED THERETO | AQUINOX PHARMACEUTICALS CANADA INC (CA) | 2016-02-04 | — | — | US | disclosed |
| EP-2970122-A1 | SHIP1 MODULATORS AND METHODS RELATED THERETO | Aquinox Pharmaceuticals (Canada) Inc. (CA) | 2016-01-20 | — | — | EP | disclosed |
| EP-2970100-A1 | SHIP1 MODULATORS AND METHODS RELATED THERETO | Aquinox Pharmaceuticals (Canada) Inc. (CA) | 2016-01-20 | — | — | EP | disclosed |
| CN-105209429-A | Ship1 modulators and methods related thereto | AQUINOX PHARMACEUTICALS INC | 2015-12-30 | — | — | CN | disclosed |
| US-9212147-B2 | Dihydroxy aromatic heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-12-15 | — | — | US | disclosed |
| US-20150336935-A1 | SHIP1 MODULATORS AND METHODS RELATED THERETO | AQUINOX PHARMACEUTICALS CANADA INC (CA) | 2015-11-26 | — | — | US | disclosed |
| US-20150328314-A1 | PHOTOCLEAVABLE DRUG CONJUGATES | THE CURATORS OF THE UNIVERSITY OF MISSOURI (US) | 2015-11-19 | — | — | US | disclosed |
| EP-2943470-A1 | SHIP1 MODULATORS AND METHODS RELATED THERETO | Aquinox Pharmaceuticals (Canada) Inc. (CA) | 2015-11-18 | — | — | EP | disclosed |
| CN-105001038-A | Novel method for synthesizing gem-dihalide compound | CANGZHOU PURUI DONGFANG SCIENCE & TECHNOLOGY CO LTD | 2015-10-28 | — | — | CN | disclosed |
| US-9161997-B2 | Contrast agents for myocardial perfusion imaging | LANTHEUS MEDICAL IMAGING, INC. | 2015-10-20 | — | — | US | disclosed |
| WO-2015112014-A1 | PROCESS FOR THE CYCLOADDITION OF A HETERO(ARYL) 1,3-DIPOLE COMPOUND WITH A (HETERO)CYCLOALKYNE | STICHTING KATHOLIEKE UNIVERSITEIT (NL) | 2015-07-30 | — | — | WO | disclosed |
| US-20150204893-A1 | TEST KIT FOR THE QUANTITATIVE DETERMINATION OF NARCOTIC DRUGS | CHIRON AS (NO) | 2015-07-23 | — | — | US | disclosed |
| CN-102617690-B | Vitamin d derivatives | CHUGAI PHARMACEUTICAL CO LTD | 2015-07-08 | — | — | CN | disclosed |
| US-20150152476-A1 | REAGENTS AND METHODS FOR DIRECT LABELING OF NUCLEOTIDES | MARKER GENE TECHNOLOGIES, INC. | 2015-06-04 | — | — | US | disclosed |
| CN-103664852-B | Preparation method of rose ether | UNIV LANGZHOU | 2015-05-13 | — | — | CN | disclosed |
| US-20150073011-A1 | Beta-Lactamase Inhibitor Compounds | ASTRAZENECA AB (SE) | 2015-03-12 | — | — | US | disclosed |
| CN-104364254-A | Heterobicyclic compounds as beta-lactamase inhibitors | ASTRAZENECA SWEDEN AB | 2015-02-18 | — | — | CN | disclosed |
| EP-2835135-A2 | Means and methods for treating pseudomonas infection | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Berlin (DE) | 2015-02-11 | — | — | EP | disclosed |
| EP-2834239-A1 | HETEROBICYCLIC COMPOUNDS AS BETA-LACTAMASE INHIBITORS | Astrazeneca AB (SE) | 2015-02-11 | — | — | EP | disclosed |
| US-8916346-B2 | Reagents and methods for direct labeling of nucleotides | Marker Gene Technology, Inc. (US) | 2014-12-23 | — | — | US | disclosed |
| WO-2014184561-A1 | FLUORO-PERHEXILINE COMPOUNDS AND THEIR THERAPEUTIC USE | THE UNIVERSITY COURT OF THE UNIVERSITY OF ABERDEEN (GB) | 2014-11-20 | — | — | WO | disclosed |
| WO-2014184561-A1 | FLUORO-PERHEXILINE COMPOUNDS AND THEIR THERAPEUTIC USE | THE UNIVERSITY COURT OF THE UNIVERSITY OF ABERDEEN (GB) | 2014-11-20 | — | — | WO | disclosed |
| US-8889894-B2 | Compounds for use in therapy | BANGOR UNIVERSITY (GB) | 2014-11-18 | — | — | US | disclosed |
| US-20140336165-A1 | DIHYDROXY AROMATIC HETEROCYCLIC COMPOUND | ASTELLAS PHARMA INC. (JP) | 2014-11-13 | — | — | US | disclosed |
| CN-104130229-A | Preparation method of cis-rose oxide | UNIV LANZHOU | 2014-11-05 | — | — | CN | disclosed |
| EP-2794633-A2 | SYNTHESIS OF ABIRATERONE AND RELATED COMPOUNDS | Crystal Pharma S.A.U (ES) | 2014-10-29 | — | — | EP | disclosed |
| WO-2014158654-A1 | SHIP1 MODULATORS AND METHODS RELATED THERETO | AQUINOX PHARMACEUTICALS INC. (CA) | 2014-10-02 | — | — | WO | disclosed |
| WO-2014143561-A1 | SHIP1 MODULATORS AND METHODS RELATED THERETO | AQUINOX PHARMACEUTICALS INC. (CA) | 2014-09-18 | — | — | WO | disclosed |
| WO-2014123900-A1 | ANTI-CANCER AND ANTI-HIV COMPOUNDS | SIRENAS MARINE DISCOVERY (US) | 2014-08-14 | — | — | WO | disclosed |
| WO-2014110036-A1 | SHIP1 MODULATORS AND METHODS RELATED THERETO | AQUINOX PHARMACEUTICALS INC. (CA) | 2014-07-17 | — | — | WO | disclosed |
| US-8728515-B2 | Adjuvants for use in vaccination | BANGOR UNIVERSITY (GB) | 2014-05-20 | — | — | US | disclosed |
| CN-101233137-B | Macrocylic inhibitors of hepatitis c virus | TIBOTEC PHARM LTD | 2014-05-07 | — | — | CN | disclosed |
| CN-103664852-A | Preparation method of rose ether | UNIV LANGZHOU | 2014-03-26 | — | — | CN | disclosed |
| US-8674088-B2 | Antiviral phosphinate compounds | GILEAD SCIENCES, INC. (US) | 2014-03-18 | — | — | US | disclosed |
| EP-2687854-A1 | Test kit for the quantitative determination of narcotic drugs | Chiron AS (NO) | 2014-01-22 | — | — | EP | disclosed |
| US-20140011992-A1 | SYNTHESIS OF ABIRATERONE AND RELATED COMPOUNDS | CRYSTAL PHARMA, S.A.U. (ES) | 2014-01-09 | — | — | US | disclosed |
| WO-2014004278-A1 | PHOTOCLEAVABLE DRUG CONJUGATES | THE CURATORS OF THE UNIVERSITY OF MISSOURI (US) | 2014-01-03 | — | — | WO | disclosed |
| US-8586744-B2 | Antiviral phosphinate compounds | GILEAD SCIENCES, INC. (US) | 2013-11-19 | — | — | US | disclosed |
| WO-2013150296-A1 | HETEROBICYCLIC COMPOUNDS AS BETA-LACTAMASE INHIBITORS | ASTRAZENECA AB (SE) | 2013-10-10 | — | — | WO | disclosed |
| EP-2620158-A1 | Adjuvants for use in vaccination | Bangor University (GB) | 2013-07-31 | — | — | EP | disclosed |
| EP-2607371-A1 | Processes for the preparation of abiraterone and related compouds | Crystal Pharma, S.A.U. (ES) | 2013-06-26 | — | — | EP | disclosed |
| US-20130150254-A1 | Reagents and methods for direct labeling of nucleotides | MARKER GENE TECHNOLOGIES, INC. | 2013-06-13 | — | — | US | disclosed |
| US-8399671-B2 | Methods for producing hydrocodone, hydromorphone or a derivative thereof | MALLINCKRODT LLC (US) | 2013-03-19 | — | — | US | disclosed |
| WO-2013030410-A2 | SYNTHESIS OF ABIRATERONE AND RELATED COMPOUNDS | CRYSTAL PHARMA, S.A.U. (ES) | 2013-03-07 | — | — | WO | disclosed |
| CN-101462994-B | Vitamin D derivatives | CHUGAI PHARMACEUTICAL CO LTD | 2012-11-28 | — | — | CN | disclosed |
| US-8304545-B2 | Quinuclidine derivative useful in the preparation of mequitazine | PIERRE FABRE MEDICAMENT (FR) | 2012-11-06 | — | — | US | disclosed |
| US-8304545-B2 | Quinuclidine derivative useful in the preparation of mequitazine | PIERRE FABRE MEDICAMENT (FR) | 2012-11-06 | — | — | US | disclosed |
| US-20120276006-A1 | CONTRAST AGENTS FOR MYOCARDIAL PERFUSION IMAGING | LANTHEUS MEDICAL IMAGING, INC. (US) | 2012-11-01 | — | — | US | disclosed |
| EP-2480555-A2 | METHODS FOR PRODUCING HYDROCODONE, HYDROMORPHONE OR A DERIVATIVE THEREOF | Mallinckrodt LLC (US) | 2012-08-01 | — | — | EP | disclosed |
| CN-102617690-A | Vitamin d derivatives | CHUGAI PHARMACEUTICAL CO LTD | 2012-08-01 | — | — | CN | disclosed |
| US-8226929-B2 | Administering to a patient a contrast agent (pyridimifen, fenazaquin) which comprises a compound that binds MC-1, and an imaging moiety, and scanning the patient using diagnostic imaging | LANTHEUS MEDICAL IMAGING, INC. (US) | 2012-07-24 | — | — | US | disclosed |
| US-8178552-B2 | 7-Azaindole derivatives and their use in the inhibition of c-Jun N-terminal kinase | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2012-05-15 | — | — | US | disclosed |
| EP-2043658-B1 | ANTIVIRAL PHOSPHINATE COMPOUNDS | GILEAD SCIENCES INC (US) | 2012-04-25 | — | — | EP | disclosed |
| US-8158784-B2 | Quinuclidine derivative useful in the preparation of mequitazine | PIERRE FABRE MEDICAMENT (FR) | 2012-04-17 | — | — | US | disclosed |
| US-8158784-B2 | Quinuclidine derivative useful in the preparation of mequitazine | PIERRE FABRE MEDICAMENT (FR) | 2012-04-17 | — | — | US | disclosed |
| US-20120088917-A1 | NEW QUINUCLIDINE DERIVATIVE USEFUL IN THE PREPARATION OF MEQUITAZINE | MIOSKOWSKI CHARLES (FR) | 2012-04-12 | — | — | US | disclosed |
| US-20120088917-A1 | NEW QUINUCLIDINE DERIVATIVE USEFUL IN THE PREPARATION OF MEQUITAZINE | MIOSKOWSKI CHARLES (FR) | 2012-04-12 | — | — | US | disclosed |
| US-8058245-B2 | Fused heterocycle derivative, medicinal composition containing the same, and medicinal use thereof | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2011-11-15 | — | — | US | disclosed |
| US-7989471-B2 | Macrocyclic inhibitors of hepatitis C virus | TIBOTEC PHARMACEUTICALS LTD. (IE) | 2011-08-02 | — | — | US | disclosed |
| EP-1912995-B1 | MACROCYLIC INHIBITORS OF HEPATITIS C VIRUS | TIBOTEC PHARM LTD (IE) | 2011-07-27 | — | — | EP | disclosed |
| US-7985744-B2 | Administering 9,10-secopregna-5,7,10(19),16- tetraene derivative to a patient for treating skin diseases such as psoriasis | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2011-07-26 | — | — | US | disclosed |
| US-20110150981-A1 | Compounds for Use in Therapy | BANGOR UNIVERSITY (GB) | 2011-06-23 | — | — | US | disclosed |
| US-20110142916-A1 | Adjuvants for Use in Vaccination | BANGOR UNIVERSITY (GB) | 2011-06-16 | — | — | US | disclosed |
| US-7951802-B2 | Use of 7-azaindoles in the inhibition of c-Jun N-terminal kinase | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2011-05-31 | — | — | US | disclosed |
| US-7951802-B2 | Use of 7-azaindoles in the inhibition of c-Jun N-terminal kinase | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2011-05-31 | — | — | US | disclosed |
| US-20110081314-A1 | ANTIVIRAL PHOSPHINATE COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2011-04-07 | — | — | US | disclosed |
| US-20110082112-A1 | ANTIVIRAL PHOSPHINATE COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2011-04-07 | — | — | US | disclosed |
| WO-2011037854-A2 | METHODS FOR PRODUCING HYDROCODONE, HYDROMORPHONE OR A DERIVATIVE THEREOF | MALLINCKRODT INC. (US) | 2011-03-31 | — | — | WO | disclosed |
| US-20110071297-A1 | Methods for Producing Hydrocodone, Hydromorphone or a Derivative Thereof | MALLINCKRODT INC. (US) | 2011-03-24 | — | — | US | disclosed |
| US-7893264-B2 | viricides comprising phosphinic acid compounds and/or mixed with carriers, nucleoside analogues, interferons or pegylated interferons; treating hepatitis C or a hepatitis C associated disorders in animals; side effect reduction | GILEAD SCIENCES, INC. (US) | 2011-02-22 | — | — | US | disclosed |
| EP-2278995-A2 | COMPOUNDS FOR USE IN THERAPY | Bangor University (GB) | 2011-02-02 | — | — | EP | disclosed |
| EP-2278996-A1 | ADJUVANTS FOR USE IN VACCINATION | Bangor University (GB) | 2011-02-02 | — | — | EP | disclosed |
| US-7807472-B2 | Methods for separation and detection of ketosteroids and other carbonyl-containing compounds | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2010-10-05 | — | — | US | disclosed |
| US-20100240698-A1 | MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS | JANSSEN SCIENCES IRELAND UC (IE) | 2010-09-23 | — | — | US | disclosed |
| US-7767721-B2 | soft agglomerates formed via reducing cuprous carboxyl compound in aqueous solution, with hydrazine; colloids; for electroconductive pastes, ink, and inkjet inks | ASAHI KASEI KABUSHIKI KAISHA (JP) | 2010-08-03 | — | — | US | disclosed |
| US-7732596-B2 | Fused heterocycle derivative, medicinal composition containing the same, and medicinal use thereof | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2010-06-08 | — | — | US | disclosed |
| US-20100105897-A1 | NOVEL QUINUCLIDINE DERIVATIVE USEFUL IN THE PREPARATION OF MEQUITAZINE | PIERRE FABRE MEDICAMENT (FR) | 2010-04-29 | — | — | US | disclosed |
| US-20100105897-A1 | NOVEL QUINUCLIDINE DERIVATIVE USEFUL IN THE PREPARATION OF MEQUITAZINE | PIERRE FABRE MEDICAMENT (FR) | 2010-04-29 | — | — | US | disclosed |
| US-20100069358-A1 | USE OF 7-AZAINDOLES IN THE INHIBITION OF C-JUN N-TERMINAL KINASE | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2010-03-18 | — | — | US | disclosed |
| US-20100069354-A1 | 7-AZAINDOLE DERIVATIVES AND THEIR USE IN THE INHIBITION OF C-JUN N-TERMINAL KINASE | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2010-03-18 | — | — | US | disclosed |
| US-20100069358-A1 | USE OF 7-AZAINDOLES IN THE INHIBITION OF C-JUN N-TERMINAL KINASE | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2010-03-18 | — | — | US | disclosed |
| US-7674401-B2 | Method of producing a thin conductive metal film | ASAHI KASEI KABUSHIKI KAISHA (JP) | 2010-03-09 | — | — | US | disclosed |
| WO-2009130506-A2 | COMPOUNDS FOR USE IN THERAPY | BANGOR UNIVERSITY (GB) | 2009-10-29 | — | — | WO | disclosed |
| WO-2009130508-A1 | ADJUVANTS FOR USE IN VACCINATION | BANGOR UNIVERSITY (GB) | 2009-10-29 | — | — | WO | disclosed |
| US-20090227491-A1 | ANTIVIRAL PHOSPHINATE COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2009-09-10 | — | — | US | disclosed |
| CN-101462994-A | Vitamin D derivatives | CHUGAI PHARMACEUTICAL CO LTD (JP) | 2009-06-24 | — | — | CN | disclosed |
| EP-2043658-A2 | ANTIVIRAL PHOSPHINATE COMPOUNDS | Gilead Sciences, Inc. (US) | 2009-04-08 | — | — | EP | disclosed |
| CN-100469764-C | Vitamin D derivatives | CHUGAI PHARMACEUTICAL CO LTD (JP) | 2009-03-18 | — | — | CN | disclosed |
| US-7491745-B2 | Pyrrole-Type compounds, compositions and methods for treating cancer or viral disease | GEMIN X PHARMACEUTICALS CANADA INC. (CA) | 2009-02-17 | — | — | US | disclosed |
| WO-2008005565-A9 | ANTIVIRAL PHOSPHINATE COMPOUNDS | GILEAD SCIENCES INC (US) | 2009-01-29 | — | — | WO | disclosed |
| EP-1713512-A4 | CONTRAST AGENTS FOR MYOCARDIAL PERFUSION IMAGING | BRISTOL MYERS SQUIBB PHARMA CO (US) | 2009-01-07 | — | — | EP | disclosed |
| WO-2008095944-A1 | 7-AZAINDOLE DERIVATIVES AND THEIR USE IN THE INHIBITION OF C-JUN N-TERMINAL KINASE | EISAI R&D MANAGEMENT CO. LTD. (JP) | 2008-08-14 | — | — | WO | disclosed |
| WO-2008095943-A1 | THE USE OF 7-AZAINDOLES IN THE INHIBITION OF C-JUN N-TERMINAL KINASE | EISAI R&D MANAGEMENT CO. LTD. (JP) | 2008-08-14 | — | — | WO | disclosed |
| CN-101233137-A | Macrocylic inhibitors of hepatitis c virus | TIBOTEC PHARM LTD (IE) | 2008-07-30 | — | — | CN | disclosed |
| US-7396953-B2 | Angiogenesis inhibitors and pharmaceutical/cosmetic applications thereof | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2008-07-08 | — | — | US | disclosed |
| CN-100395059-C | Metal oxide dispersion | ASAHI CHEMICAL IND (JP) | 2008-06-18 | — | — | CN | disclosed |
| US-20080130474-A1 | Optical Recording Materials Having High Stroage Density | SCHMIDHALTER BEAT | 2008-06-05 | — | — | US | disclosed |
| US-20080130474-A1 | Optical Recording Materials Having High Stroage Density | SCHMIDHALTER BEAT | 2008-06-05 | — | — | US | disclosed |
| US-20080112884-A1 | CONTRAST AGENTS FOR MYOCARDIAL PERFUSION IMAGING | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2008-05-15 | — | — | US | disclosed |
| EP-1912995-A1 | MACROCYLIC INHIBITORS OF HEPATITIS C VIRUS | Tibotec Pharmaceuticals Ltd. (IE) | 2008-04-23 | — | — | EP | disclosed |
| US-7344702-B2 | Contrast agents for myocardial perfusion imaging | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2008-03-18 | — | — | US | disclosed |
| US-20080057031-A1 | Antiviral phosphinate compounds | GILEAD SCIENCES, INC. (US) | 2008-03-06 | — | — | US | disclosed |
| CN-100364995-C | Production of galantamine | UNIV LANZHOU (CN) | 2008-01-30 | — | — | CN | disclosed |
| WO-2008005565-A2 | ANTIVIRAL PHOSPHINATE COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2008-01-10 | — | — | WO | disclosed |
| CN-100357280-C | Dihydronaphthalene devivatives and drugs contanining these compounds as active ingrdeient | ONO PHARMACENTICAL CO LTD (JP) | 2007-12-26 | — | — | CN | disclosed |
| US-20070197450-A1 | Fused heterocycle derivative, medicinal composition containing the same, and medicinal use thereof | KISSEI PHARMACEUTICAL CO., LTD. | 2007-08-23 | — | — | US | disclosed |
| US-20070197449-A1 | Fused heterocycle derivative, medicinal composition containing the same, and medicinal use thereof | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2007-08-23 | — | — | US | disclosed |
| CN-1332885-C | Copper oxide ultrafine particle | ASAHI CHEMICAL IND (JP) | 2007-08-22 | — | — | CN | disclosed |
| EP-1354879-B1 | DIHYDRONAPHTHALENE DERIVATIVE COMPOUNDS AND DRUGS CONTAINING THESE COMPOUNDS AS THE ACTIVE INGREDIENT | ONO PHARMACEUTICAL CO (JP) | 2007-08-15 | — | — | EP | disclosed |
| US-20070167519-A1 | Novel Angiogenesis inhibitors and pharmaceutical/cosmetic applications thereof | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2007-07-19 | — | — | US | disclosed |
| US-7220864-B2 | Dihydronaphthalene derivative compounds and agent comprising the derivative as active ingredient | ONO PHARMACEUTICAL CO., LTD. (JP) | 2007-05-22 | — | — | US | disclosed |
| EP-1763500-A1 | NOVEL ANGIOGENESIS INHIBITORS AND PHARMACEUTICAL AND COSMETIC USE THEREOF | Galderma Research & Development, S.N.C. (FR) | 2007-03-21 | — | — | EP | disclosed |
| US-20070037856-A1 | e.g. 2-Ethyl-11-((3-methoxy-5-(1H-pyrrol-2-yl)-2H-pyrrol-2-ylidene)methyl)-10-azabicyclo[7.2.1]dodeca-9(12),11-diene; anticarcinogenic agent; antiproliferative agent, viricide | GEMIN X BIOTECHNOLOGIES INC. (CA) | 2007-02-15 | — | — | US | disclosed |
| WO-2007014919-A1 | MACROCYLIC INHIBITORS OF HEPATITIS C VIRUS | TIBOTEC PHARMACEUTICALS LTD. (IE) | 2007-02-08 | — | — | WO | disclosed |
| US-7166416-B2 | Protecting groups in polymers, photoresists and processes for microlithography | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 2007-01-23 | — | — | US | disclosed |
| US-7166416-B2 | Protecting groups in polymers, photoresists and processes for microlithography | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 2007-01-23 | — | — | US | disclosed |
| US-7166416-B2 | Protecting groups in polymers, photoresists and processes for microlithography | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 2007-01-23 | — | — | US | disclosed |
| US-20060287304-A1 | Dihydronaphthalene derivative compounds and agent comprising the derivative as active ingredient | ONO PHARMACEUTICAL CO., LTD. | 2006-12-21 | — | — | US | disclosed |
| US-7144912-B2 | Pyrrole-type compounds, compositions, and methods for treating cancer, treating viral diseases and causing immunosuppression | GEMIN X BIOTECHNOLOGIES INC. (CA) | 2006-12-05 | — | — | US | disclosed |
| EP-1726586-A1 | Dihydronaphthalene derivative compounds and agent comprising the derivative as active ingredient | ONO PHARMACEUTICAL CO., LTD. (JP) | 2006-11-29 | — | — | EP | disclosed |
| EP-1724277-A1 | FUSED HETEROCYCLE DERIVATIVE, MEDICINAL COMPOSITION CONTAINING THE SAME, AND MEDICINAL USE THEREOF | Kissei Pharmaceutical Co., Ltd. (JP) | 2006-11-22 | — | — | EP | disclosed |
| EP-1721904-A1 | FUSED HETEROCYCLE DERIVATIVE, MEDICINAL COMPOSITION CONTAINING THE SAME, AND MEDICINAL USE THEREOF | Kissei Pharmaceutical Co., Ltd. (JP) | 2006-11-15 | — | — | EP | disclosed |
| EP-1713512-A2 | CONTRAST AGENTS FOR MYOCARDIAL PERFUSION IMAGING | Bristol-Myers Squibb Pharma Company (US) | 2006-10-25 | — | — | EP | disclosed |
| US-7074777-B2 | Vitamin D derivatives | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2006-07-11 | — | — | US | disclosed |
| US-20060098065-A1 | Copper oxide ultrafine particle | ASAHI KASEI KABUSHIKI KAISHA (JP) | 2006-05-11 | — | — | US | disclosed |
| WO-2006010859-A1 | NOVEL ANGIOGENESIS INHIBITORS AND PHARMACEUTICAL AND COSMETIC USE THEREOF | GALDERMA RESEARCH & DEVELOPMENT, S.N.C. (FR) | 2006-02-02 | — | — | WO | disclosed |
| US-20060009479-A1 | Process for the synthesis of hydromorphone | BAILEY TIMOTHY S | 2006-01-12 | — | — | US | disclosed |
| CN-1720196-A | Copper oxide ultrafine particle | ASAHI CHEMICAL IND (JP) | 2006-01-11 | — | — | CN | disclosed |
| US-20050191238-A1 | Contrast agents for myocardial perfusion imaging | LANTHEUS MEDICAL IMAGING, INC. | 2005-09-01 | — | — | US | disclosed |
| WO-2005079391-A2 | CONTRAST AGENTS FOR MYOCARDIAL PERFUSION IMAGING | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2005-09-01 | — | — | WO | disclosed |
| US-20050191579-A1 | Protecting groups in polymers, photoresists and processes for microlithography | FEIRING ANDREW E (US) | 2005-09-01 | — | — | US | disclosed |
| US-20050181514-A1 | Methods for separation and detection of ketosteroids and other carbonyl-containing compounds | HEALTH AND HUMAN SERVICES, THE GOVERNMENT OF THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE DEPARTMENT OF | 2005-08-18 | — | — | US | disclosed |
| US-6899995-B2 | Protecting groups in polymers, photoresists and processes for microlithography | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 2005-05-31 | — | — | US | disclosed |
| CN-1606481-A | Metal oxide dispersion | ASAHI CHEMICAL IND (JP) | 2005-04-13 | — | — | CN | disclosed |
| US-20050069648-A1 | Metal oxide dispersion | ASAHI KASEI KABUSHIKI KAISHA (JP) | 2005-03-31 | — | — | US | disclosed |
| US-20050049292-A1 | Pyrrole-type compounds, compositions, and methods for treating cancer, treating viral diseases and causing immunosuppression | GEMIN X PHARMACEUTICALS CANADA INC. (CA) | 2005-03-03 | — | — | US | disclosed |
| US-20040138213-A1 | Dihydronaphthalene derivative compounds and drugs containing these compounds as the active ingredient | ONO PHARMACEUTICAL CO., LTD. (JP) | 2004-07-15 | — | — | US | disclosed |
| EP-1431286-A2 | Prodigiosin derivatives for treating cancer or viral diseases | Gemin X Biotechnologies Inc. (CA) | 2004-06-23 | — | — | EP | disclosed |
| CN-1489582-A | Dihydronaphthalene devivatives and drugs contanining these compounds as active ingrdeient | СҰҩƷ��ҵ��ʽ���� | 2004-04-14 | — | — | CN | disclosed |
| US-20040023157-A1 | Protecting groups in polymers, photoresists and processes for microlithography | E.I. DU PONT DE NEMOURS AND COMPANY | 2004-02-05 | — | — | US | disclosed |
| US-20040019023-A1 | Vitamin d derivatives | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2004-01-29 | — | — | US | disclosed |
| US-20040014987-A1 | Pyrrole-Type compounds, compositions, and methods for treating cancer or viral diseases | GEMIN X BIOTECHNOLOGIES INC. | 2004-01-22 | — | — | US | disclosed |
| WO-2003089921-A1 | METHODS FOR SEPARATION AND DETECTION OF KETOSTEROIDS AND OTHER CARBONYL-CONTAINING COMPOUNDS | THE GOVERNMENT OF THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2003-10-30 | — | — | WO | disclosed |
| EP-1354879-A1 | DIHYDRONAPHTHALENE DERIVATIVE COMPOUNDS AND DRUGS CONTAINING THESE COMPOUNDS AS THE ACTIVE INGREDIENT | ONO PHARMACEUTICAL CO., LTD. (JP) | 2003-10-22 | — | — | EP | disclosed |
| US-20030195176-A1 | Vitamin d derivatives | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2003-10-16 | — | — | US | disclosed |
| EP-1340125-A2 | PROTECTING GROUPS IN POLYMERS, PHOTORESISTS AND PROCESSES FOR MICROLITHOGRAPHY | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 2003-09-03 | — | — | EP | disclosed |
| CN-1436170-A | vitamin D derivatives | CHUGAI PHARMACEUTICAL CO LTD (JP) | 2003-08-13 | — | — | CN | disclosed |
| US-6602879-B2 | For inhibiting the replication or infectivity of a virus; therapy | GEMIN X BIOTECHNOLOGIES INC. (CA) | 2003-08-05 | — | — | US | disclosed |
| EP-1295871-A1 | VITAMIN D DERIVATIVES | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2003-03-26 | — | — | EP | disclosed |
| EP-1275643-A1 | VITAMIN D DERIVATIVES | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2003-01-15 | — | — | EP | disclosed |
| US-20030009032-A1 | Pyrrole-type compounds, compositions, and methods for treating cancer or viral diseases | GEMIN X PHARMACEUTICALS CANADA INC. (CA) | 2003-01-09 | — | — | US | disclosed |
| US-20020173515-A1 | Antiproliferative substituted 5-thiapyrimidinone and 5-selenopyrimidinone compounds | VARNEY MICHAEL D (US) | 2002-11-21 | — | — | US | disclosed |
| US-6407244-B1 | ANTIPROLIFERATIVE AGENT | GEMIN X BIOTECHNOLOGIES INC. (CA) | 2002-06-18 | — | — | US | disclosed |
| WO-2002044845-A2 | PROTECTING GROUPS IN POLYMERS, PHOTORESISTS AND PROCESSES FOR MICROLITHOGRAPHY | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 2002-06-06 | — | — | WO | disclosed |
| EP-0840740-B1 | NEW INHIBITORS OF PLATELET AGGREGATION | ASTRAZENECA AB (SE) | 2002-05-02 | — | — | EP | disclosed |
| US-6323210-B2 | TRANSFERASE INHIBITOR | AGOURON PHARMACEUTICALS, INC. | 2001-11-27 | — | — | US | disclosed |
| US-20010018443-A1 | Antiproliferative substituted 5-thiapyrimidinone and 5-selenopyrimidinone compounds | VARNEY MICHAEL D (US) | 2001-08-30 | — | — | US | disclosed |
| CN-1069321-C | Novel platelet aggregation inhibitors | ASTRAZENECA AB (SE) | 2001-08-08 | — | — | CN | disclosed |
| US-6207670-B1 | USE TO INHIBIT GROWTH AND PROLIFERATION OF CELLS OF HIGHER ORGANISMS AND MICROORGANISMS SUCH AS BACTERIA, YEAST AND FUNGI | AGOURON PHARMACEUTICALS, INC. | 2001-03-27 | — | — | US | disclosed |
| US-6153322-A | Methods for making fluorinated surface modifying agents, methods of using same and products made using same | HOUSTON, UNIVERSITY OF | 2000-11-28 | — | — | US | disclosed |
| US-6114468-A | Synthetic resins for use in solid phase synthesis | NOVARTIS AG (CH) | 2000-09-05 | — | — | US | disclosed |
| US-RE36784-E | Chemoprotective isothiocyanates | THE JOHNS HOPKINS UNIVERSITY (US) | 2000-07-18 | — | — | US | disclosed |
| EP-0743939-B1 | ARALKOXY AND ARALKYLTHIO SUBSTITUTED AZACYCLIC COMPOUNDS AS TACHYKININ ANTAGONISTS | MERCK SHARP & DOHME (GB) | 2000-05-10 | — | — | EP | disclosed |
| EP-0674516-B1 | ANTIPROLIFERATIVE SUBSTITUTED 5-THIAPYRIMIDINONE AND 5-SELENOPYRIMIDINONE COMPOUNDS | AGOURON PHARMA (US) | 2000-02-02 | — | — | EP | disclosed |
| US-5945427-A | INHIBIT GROWTH AND PROLIFERATION OF CELLS OF HIGHER ORGANISMS AND MICRORGANISMS SUCH AS FUNGI, BACTERIA AND YEASTS; TREATMENT FOR TUMORS, INFLAMMATION, PSORIASIS; IMMUNOSUPPRESSIVE ACTIVITY | AGOURON PHARMACEUTICALS, INC. (US) | 1999-08-31 | — | — | US | disclosed |
| US-5852005-A | Tetracyclic triterpenes | NOVARTIS AG (CH) | 1998-12-22 | — | — | US | disclosed |
| CN-1195353-A | Novel platelet aggregation inhibitors | ASTRA PHARMA PROD (GB) | 1998-10-07 | — | — | CN | disclosed |
| WO-1998040169-A1 | METHODS FOR MAKING FLUORINATED SURFACE MODIFYING AGENTS, METHODS OF USING SAME AND PRODUCTS MADE USING SAME | THE UNIVERSITY OF HOUSTON (US) | 1998-09-17 | — | — | WO | disclosed |
| US-5760240-A | TAXOIDS HAVING AROMATIC RING; WATER SOLUBLE DERIVATIVES | THE SCRIPPS RESEARCH INSTITUTE (US) | 1998-06-02 | — | — | US | disclosed |
| EP-0840740-A1 | NEW INHIBITORS OF PLATELET AGGREGATION | Astra Pharmaceuticals Limited (GB) | 1998-05-13 | — | — | EP | disclosed |
| US-5747496-A | Inhibitors of platelet aggregation | ASTRA PHARMACEUTICALS LIMITED (GB) | 1998-05-05 | — | — | US | disclosed |
| US-5739141-A | Antiproliferative substituted 5-thiapyrimidinone and 5-selenopyrimidinone compounds | AGOURON PHARMACEUTICALS, INC. (US) | 1998-04-14 | — | — | US | disclosed |
| US-5726312-A | Methods for preparing antiproliferative 5-substituted pyrimidone compounds | AGOURON PHARMACEUTICALS, INC. (US) | 1998-03-10 | — | — | US | disclosed |
| US-5686463-A | Oxadiazoles useful in the treatment of senile dementia | MERCK, SHARP & DOHME, LTD. (GB) | 1997-11-11 | — | — | US | disclosed |
| EP-0801653-A3 | — | SANDOZ LTD | 1997-10-29 | — | — | EP | disclosed |
| EP-0801653-A2 | TETRACYCLIC TRITERPENES | SANDOZ LTD. (CH) | 1997-10-22 | — | — | EP | disclosed |
| US-5665883-A | Aralkoxy and aralkylthio substituted azacyclic compounds as tachykinin antagonists | MERCK SHARP & DOHME LIMITED (GB) | 1997-09-09 | — | — | US | disclosed |
| US-5599937-A | Heteroaromatic quinuclidinenes, their use and preparation | PHARMACIA AB (SE) | 1997-02-04 | — | — | US | disclosed |
| WO-1997003084-A1 | NEW INHIBITORS OF PLATELET AGGREGATION | ASTRA PHARMACEUTICALS LTD. (GB) | 1997-01-30 | — | — | WO | disclosed |
| EP-0743939-A1 | ARALKOXY AND ARALKYLTHIO SUBSTITUTED AZACYCLIC COMPOUNDS AS TACHYKININ ANTAGONISTS | MERCK SHARP & DOHME LTD. (GB) | 1996-11-27 | — | — | EP | disclosed |
| EP-0729459-A1 | PHENYL-ALKYL IMIDAZOLES AS H3-RECEPTOR ANTAGONISTS | SCHERING CORPORATION (US) | 1996-09-04 | — | — | EP | disclosed |
| WO-1996003419-A1 | TETRACYCLIC TRITERPENES | SANDOZ LTD. (CH) | 1996-02-08 | — | — | WO | disclosed |
| US-5481007-A | CONVERGENT SYNTHESIS OF SYSTEMS OF INTACT RING FRAMEWORK OF TAXOL BY PROVIDING ACTIVATED MONO- AND BICYCLIC RING INTERMEDIATES | THE SCRIPPS RESEARCH INSTITUTE (US) | 1996-01-02 | — | — | US | disclosed |
| EP-0674516-A4 | — | — | 1995-10-25 | — | — | EP | disclosed |
| US-5461169-A | Total synthesis of taxol and taxol analogs | THE SCRIPPS RESEARCH INSTITUTE (US) | 1995-10-24 | — | — | US | disclosed |
| EP-0674516-A1 | ANTIPROLIFERATIVE SUBSTITUTED 5-THIAPYRIMIDINONE AND 5-SELENOPYRIMIDINONE COMPOUNDS | AGOURON PHARMACEUTICALS, INC. (US) | 1995-10-04 | — | — | EP | disclosed |
| WO-1995021819-A1 | ARALKOXY AND ARALKYLTHIO SUBSTITUTED AZACYCLIC COMPOUNDS AS TACHYKININ ANTAGONISTS | MERCK SHARP & DOHME LIMITED (GB) | 1995-08-17 | — | — | WO | disclosed |
| WO-1995014007-A1 | PHENYL-ALKYL IMIDAZOLES AS H3-RECEPTOR ANTAGONISTS | SCHERING CORPORATION (US) | 1995-05-26 | — | — | WO | disclosed |
| US-5411986-A | Chemoprotective isothiocyanates | THE JOHNS HOPKINS UNIVERSITY (US) | 1995-05-02 | — | — | US | disclosed |
| EP-0640082-A1 | HETEROAROMATIC QUINUCLIDINENES, THEIR USE AND PREPARATION | Pharmacia & Upjohn Aktiebolag (SE) | 1995-03-01 | — | — | EP | disclosed |
| WO-1994019948-A9 | CHEMOPROTECTIVE ISOTHIOCYANATES | — | 1994-11-10 | — | — | WO | disclosed |
| WO-1994019948-A1 | CHEMOPROTECTIVE ISOTHIOCYANATES | CHO CHEON GYU (US) | 1994-09-15 | — | — | WO | disclosed |
| EP-0570514-A4 | METHYLENE PHOSPHONATE NUCLEOSIDE ANALOGS AND OLIGONUCLEOTIDE ANALOGS MADE THEREFROM | GILEAD SCIENCES INC (US) | 1994-08-17 | — | — | EP | disclosed |
| EP-0233267-B1 | SMECTIC CRYSTAL PHASES | MERCK PATENT GMBH (DE) | 1994-08-03 | — | — | EP | disclosed |
| WO-1994013295-A1 | ANTIPROLIFERATIVE SUBSTITUTED 5-THIAPYRIMIDINONE AND 5-SELENOPYRIMIDINONE COMPOUNDS | AGOURON PHARMACEUTICALS, INC. (US) | 1994-06-23 | — | — | WO | disclosed |
| EP-0310268-B1 | Substituted cycloalkanols | AMERICAN HOME PROD (US) | 1994-02-02 | — | — | EP | disclosed |
| EP-0239309-B1 | Oxadiazoles useful in the treatment of senile dementia | MERCK SHARP & DOHME (GB) | 1994-01-12 | — | — | EP | disclosed |
| WO-1993023395-A1 | HETEROAROMATIC QUINUCLIDINENES, THEIR USE AND PREPARATION | KABI PHARMACIA AB (SE) | 1993-11-25 | — | — | WO | disclosed |
| EP-0570514-A1 | METHYLENE PHOSPHONATE NUCLEOSIDE ANALOGS AND OLIGONUCLEOTIDE ANALOGS MADE THEREFROM | GILEAD SCIENCES, INC. (US) | 1993-11-24 | — | — | EP | disclosed |
| US-5219859-A | Chloesterol acyltransferase inhibitors; antilipemic agents; antidiabetic agents; atherosclerosis | LIPHA, LYONNAISE INDUSTRIELLE PHARMACEUTIQUE (FR) | 1993-06-15 | — | — | US | disclosed |
| US-5180521-A | Liquid crystal displays, cyclohexyl nitriles | MERCK PATENT GESELLSCHAFT MIT BESCHRAENKTER HAFTUNG (DE) | 1993-01-19 | — | — | US | disclosed |
| WO-1992013869-A1 | METHYLENE PHOSPHONATE NUCLEOSIDE ANALOGS AND OLIGONUCLEOTIDE ANALOGS MADE THEREFROM | GILEAD SCIENCES, INC. (US) | 1992-08-20 | — | — | WO | disclosed |
| US-5075032-A | Electrooptics, switches, displays | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 1991-12-24 | — | — | US | disclosed |
| EP-0257049-B1 | CHIRAL COMPOUNDS | MERCK PATENT GmbH (DE) | 1990-08-01 | — | — | EP | disclosed |
| US-4886620-A | Smectic liquid-crystalline phases | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 1989-12-12 | — | — | US | disclosed |
| EP-0215120-B1 | CYCLOHEXANE DERIVATIVES | MERCK PATENT GmbH (DE) | 1989-08-23 | — | — | EP | disclosed |
| US-4846998-A | LIQUID CRYSTALS, ESTERS, NITRILES; ETHERS, HYDROCARBONS | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 1989-07-11 | — | — | US | disclosed |
| US-4826844-A | ANTIDEPRESSANT, ANXIOLYTIC AGENT | AMERICAN HOME PRODUCTS CORPORATION (US) | 1989-05-02 | — | — | US | disclosed |
| EP-0310268-A2 | Substituted cycloalkanols | AMERICAN HOME PRODUCTS CORPORATION (US) | 1989-04-05 | — | — | EP | disclosed |
| US-4755599-A | 3-phenyl-2-propeneamine derivatives, their preparation and composition containing them | RHONE-POULENC SANTE (FR) | 1988-07-05 | — | — | US | disclosed |
| US-4745191-A | 1-((A-substituted phenyl-ω-substituted piperazinyl)alkenyl) cyclohexanol | AMERICAN HOME PRODUCTS CORPORATION (US) | 1988-05-17 | — | — | US | disclosed |
| EP-0257049-A1 | CHIRAL COMPOUNDS. | MERCK PATENT GMBH (DE) | 1988-03-02 | — | — | EP | disclosed |
| CN-87102972-A | Treatment senile dementia oxadiazoles useful | — | 1987-11-18 | — | — | CN | disclosed |
| EP-0239309-A2 | Oxadiazoles useful in the treatment of senile dementia | MERCK SHARP & DOHME LTD. (GB) | 1987-09-30 | — | — | EP | disclosed |
| WO-1987005015-A1 | CHIRAL COMPOUNDS | MERCK Patent Gesellschaft mit beschränkter Haftung (DE) | 1987-08-27 | — | — | WO | disclosed |
| EP-0233267-A1 | SMECTIC CRYSTAL PHASES. | MERCK PATENT GMBH (DE) | 1987-08-26 | — | — | EP | disclosed |
| EP-0127816-B1 | TRANS-DECALINCARBONITRILES | MERCK PATENT GmbH (DE) | 1987-08-19 | — | — | EP | disclosed |
| US-4686309-A | ANTIDEPRESSANTS | RHONE-POULENC SANTE (FR) | 1987-08-11 | — | — | US | disclosed |
| WO-1987001717-A2 | SMECTIC CYSTAL PHASES | MERCK Patent Gesellschaft mit beschränkter Haftung (DE) | 1987-03-26 | — | — | WO | disclosed |
| EP-0215120-A1 | CYCLOHEXANE DERIVATIVES. | MERCK PATENT GMBH (DE) | 1987-03-25 | — | — | EP | disclosed |
| US-4628104-A | ANTIANAEROBIC AGENTS | G. D. SEARLE & CO. (US) | 1986-12-09 | — | — | US | disclosed |
| WO-1986005486-A1 | CYCLOHEXANE DERIVATIVES | MERCK Patent Gesellschaft mit beschränkter Haftung (DE) | 1986-09-25 | — | — | WO | disclosed |
| US-4600528-A | Decalin-carbonitriles | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 1986-07-15 | — | — | US | disclosed |
| EP-0174071-A2 | Dihydropyridine derivatives and their production, formulation and use as pharmaceuticals | FISONS plc (GB) | 1986-03-12 | — | — | EP | disclosed |
| EP-0174071-A2 | Dihydropyridine derivatives and their production, formulation and use as pharmaceuticals | FISONS plc (GB) | 1986-03-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (50 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130150254-A1 | Reagents and methods for direct labeling of nucleotides | DUT, DNTT, NUDT1 | FABP4 1894/4885FABP3 2789/4885FABP5 2062/4885 |
| US-11059799-B2 | Process for preparation of eribulin and intermediates thereof | ERLIN1, ERLIN2, MAN1B1 | FABP4 4491/4885FABP3 4499/4885FABP5 3474/4885 |
| US-20230037322-A1 | Cytotoxic Actin-Targeting Compounds | ACTB, ACTR2, MYC | FABP4 1706/4885FABP3 2565/4885FABP5 2187/4885 |
| US-20180009763-A1 | CONTRAST AGENTS FOR MYOCARDIAL PERFUSION IMAGING | TNNI3, TNNT2, FABP3 | FABP4 235/4885FABP3 3/4885FABP5 129/4885 |
| US-12049445-B2 | Compounds having S1P5 receptor agonistic activity | S1PR5, S1PR1, S1PR4 | FABP4 1689/4885FABP3 1954/4885FABP5 411/4885 |
| US-20180155359-A9 | SHIP1 MODULATORS AND METHODS RELATED THERETO | PPM1D, PPP1R7, PPM1A | FABP4 3339/4885FABP3 1043/4885FABP5 2577/4885 |
| US-20190023709-A1 | SHIP1 MODULATORS AND METHODS RELATED THERETO | PPM1D, PPP1R1B, PPM1A | FABP4 3927/4885FABP3 2882/4885FABP5 4138/4885 |
| US-20140011992-A1 | SYNTHESIS OF ABIRATERONE AND RELATED COMPOUNDS | HSD17B7, CYP17A1, CYP21A2 | FABP4 1943/4885FABP3 3350/4885FABP5 2575/4885 |
| US-20080112884-A1 | CONTRAST AGENTS FOR MYOCARDIAL PERFUSION IMAGING | TNNI3, TNNT2, FABP3 | FABP4 235/4885FABP3 3/4885FABP5 129/4885 |
| US-12239639-B2 | Cytotoxic actin-targeting compounds | ACTB, ACTR2, MYC | FABP4 1706/4885FABP3 2565/4885FABP5 2187/4885 |
| US-20080057031-A1 | Antiviral phosphinate compounds | PHOSPHO1, MAVS, ITPA | FABP4 2749/4885FABP3 2770/4885FABP5 1875/4885 |
| US-20050049292-A1 | Pyrrole-type compounds, compositions, and methods for treating cancer, treating viral diseases and causing immunosuppression | PYCR1, ZC3HAV1, POLI | FABP4 4320/4885FABP3 4474/4885FABP5 3147/4885 |
| US-10272081-B2 | SHIP1 modulators and methods related thereto | PPP1R1B, PPM1A, PPM1D | FABP4 3987/4885FABP3 2940/4885FABP5 4053/4885 |
| US-20240327342-A1 | COMPOUNDS HAVING S1P5 RECEPTOR AGONISTIC ACTIVITY | S1PR5, S1PR1, S1PR4 | FABP4 1689/4885FABP3 1954/4885FABP5 411/4885 |
| US-20040014987-A1 | Pyrrole-Type compounds, compositions, and methods for treating cancer or viral diseases | POLI, PYCR1, ZC3HAV1 | FABP4 4351/4885FABP3 4486/4885FABP5 3558/4885 |
| US-11198672-B2 | Compounds having S1P5 receptor agonistic activity | S1PR5, S1PR1, S1PR4 | FABP4 1689/4885FABP3 1954/4885FABP5 411/4885 |
| US-20090227491-A1 | ANTIVIRAL PHOSPHINATE COMPOUNDS | PHOSPHO1, MAVS, ITPA | FABP4 2749/4885FABP3 2770/4885FABP5 1875/4885 |
| US-20150336935-A1 | SHIP1 MODULATORS AND METHODS RELATED THERETO | PPM1A, PPM1D, PPP1R1B | FABP4 3733/4885FABP3 2878/4885FABP5 3865/4885 |
| US-20110142916-A1 | Adjuvants for Use in Vaccination | NR1H3, NR1H2, INTS6 | FABP4 2691/4885FABP3 3862/4885FABP5 1401/4885 |
| US-20060009479-A1 | Process for the synthesis of hydromorphone | DHPS, CYP8B1, QDPR | FABP4 3521/4885FABP3 4310/4885FABP5 3561/4885 |
| US-20210139538-A1 | METHOD OF PREPARING STAPLED PEPTIDES | VIP, IAPP, HM13 | FABP4 3405/4885FABP3 2488/4885FABP5 2854/4885 |
| US-20030195176-A1 | Vitamin d derivatives | CYP24A1, VDR, CYP2R1 | FABP4 631/4885FABP3 1922/4885FABP5 1403/4885 |
| US-20210087141-A1 | COMPOUNDS HAVING S1P5 RECEPTOR AGONISTIC ACTIVITY | S1PR5, S1PR1, S1PR4 | FABP4 1689/4885FABP3 1954/4885FABP5 411/4885 |
| US-20200247858-A1 | AGENTS MODULATING BETA-CATENIN FUNCTIONS AND METHODS THEREOF | CTNNB1, CTNNBL1, CTNNA1 | FABP4 558/4885FABP3 376/4885FABP5 1175/4885 |
| US-20110081314-A1 | ANTIVIRAL PHOSPHINATE COMPOUNDS | PHOSPHO1, MAVS, ITPA | FABP4 2749/4885FABP3 2770/4885FABP5 1875/4885 |
| US-10174046-B2 | SHIP1 modulators and methods related thereto | PPM1D, PPP1R7, PPM1A | FABP4 3339/4885FABP3 1043/4885FABP5 2577/4885 |
| US-20160083387-A1 | SHIP1 MODULATORS AND METHODS RELATED THERETO | PPM1D, PPP1R1B, PPM1A | FABP4 3927/4885FABP3 2882/4885FABP5 4138/4885 |
| US-20170253596-A2 | SHIP1 MODULATORS AND METHODS RELATED THERETO | PPM1D, PPP1R1B, PPM1A | FABP4 3927/4885FABP3 2882/4885FABP5 4138/4885 |
| US-20070167519-A1 | Novel Angiogenesis inhibitors and pharmaceutical/cosmetic applications thereof | FLT1, VEGFA, FGF1 | FABP4 620/4885FABP3 2461/4885FABP5 888/4885 |
| US-20190177291-A1 | PROCESS FOR PREPARATION OF ERIBULIN AND INTERMEDIATES THEREOF | ERLIN1, ERLIN2, MAN1B1 | FABP4 4491/4885FABP3 4499/4885FABP5 3474/4885 |
| US-20050191238-A1 | Contrast agents for myocardial perfusion imaging | TNNI3, TNNT2, FABP3 | FABP4 235/4885FABP3 3/4885FABP5 129/4885 |
| US-20170247389-A2 | SHIP1 MODULATORS AND METHODS RELATED THERETO | PPM1D, PPP1R7, PPM1A | FABP4 3339/4885FABP3 1043/4885FABP5 2577/4885 |
| US-11976083-B2 | Inhibitors of peptidylarginine deiminases | PADI4, PADI2, PADI1 | FABP4 1097/4885FABP3 836/4885FABP5 2182/4885 |
| US-20190127333-A1 | CONTRAST AGENTS FOR MYOCARDIAL PERFUSION IMAGING | TNNI3, TNNT2, FABP3 | FABP4 235/4885FABP3 3/4885FABP5 129/4885 |
| US-11198713-B2 | Agents modulating beta-catenin functions and methods thereof | CTNNB1, CTNNBL1, CTNNA1 | FABP4 558/4885FABP3 376/4885FABP5 1175/4885 |
| US-20180360828-A9 | SHIP1 MODULATORS AND METHODS RELATED THERETO | PPP1R1B, PPM1A, PPM1D | FABP4 3987/4885FABP3 2940/4885FABP5 4053/4885 |
| US-20220055986-A1 | COMPOUNDS HAVING S1P5 RECEPTOR AGONISTIC ACTIVITY | S1PR5, S1PR1, S1PR4 | FABP4 1689/4885FABP3 1954/4885FABP5 411/4885 |
| US-20190125870-A1 | PHOTOCLEAVABLE DRUG CONJUGATES | DHFR, CES2, STRA6 | FABP4 466/4885FABP3 1545/4885FABP5 1892/4885 |
| US-20220048920-A1 | PROCESS FOR THE CYCLOADDITION OF A (HETERO)ARYL 1,3-DIPOLE COMPOUND WITH A (HETERO)CYCLOALKYNE | AHR, CYP1B1, NAT1 | FABP4 4603/4885FABP3 4625/4885FABP5 4320/4885 |
| US-20040019023-A1 | Vitamin d derivatives | VDR, CYP24A1, CYP2R1 | FABP4 138/4885FABP3 690/4885FABP5 512/4885 |
| US-20160175290-A1 | BETA-LACTAMASE INHIBITOR COMPOUNDS | LCT, MGAM, SI | FABP4 4791/4885FABP3 3984/4885FABP5 3706/4885 |
| US-20170224682-A1 | SHIP1 MODULATORS AND METHODS RELATED THERETO | PPP1R1B, PPM1A, PPM1D | FABP4 3987/4885FABP3 2940/4885FABP5 4053/4885 |
| US-10155771-B2 | Selective reduction of morphinan alkaloids | QDPR, CA5B, COX5B | FABP4 4510/4885FABP3 4492/4885FABP5 3013/4885 |
| US-11369594-B2 | Cytotoxic actin-targeting compounds | ACTB, ACTR2, MYC | FABP4 1706/4885FABP3 2565/4885FABP5 2187/4885 |
| US-20150328314-A1 | PHOTOCLEAVABLE DRUG CONJUGATES | CD47, CES2, STRA6 | FABP4 210/4885FABP3 927/4885FABP5 1166/4885 |
| US-20070197450-A1 | Fused heterocycle derivative, medicinal composition containing the same, and medicinal use thereof | SLC5A1, SLC5A2, GPR119 | FABP4 172/4885FABP3 585/4885FABP5 1339/4885 |
| US-20060287304-A1 | Dihydronaphthalene derivative compounds and agent comprising the derivative as active ingredient | SREBF1, NR1H2, NR1H3 | FABP4 25/4885FABP3 55/4885FABP5 323/4885 |
| US-20070197449-A1 | Fused heterocycle derivative, medicinal composition containing the same, and medicinal use thereof | SLC5A1, SLC5A2, GPR119 | FABP4 234/4885FABP3 830/4885FABP5 1929/4885 |
| US-20230002412-A1 | INHIBITORS OF PEPTIDYLARGININE DEIMINASES | PADI4, PADI2, PADI1 | FABP4 1097/4885FABP3 836/4885FABP5 2182/4885 |
| US-20160039771-A1 | DIHYDROXY AROMATIC HETEROCYCLIC COMPOUND | DAO, DDO, DDC | FABP4 2253/4885FABP3 3484/4885FABP5 3420/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.